NCT06939439 is a Phase 3 clinical trial of Tislelizumab + SOX Chemotherapy in Gastric Cancer Stage III, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT06939439?

NCT06939439 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT06939439?

Interventions in NCT06939439: Tislelizumab + SOX Chemotherapy, SOX Chemotherapy.

What condition does NCT06939439 study?

NCT06939439 studies Gastric Cancer Stage III.

Is NCT06939439 still recruiting?

NCT06939439 is currently active, enrolled. Last updated 1 July 2025.

Last reviewed 2025-07-01 · How we verify

NCT06939439

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

Active, enrolled Phase 3 Last updated 1 July 2025

What this trial tests

Phase 3 trial testing Tislelizumab + SOX Chemotherapy in Gastric Cancer Stage III in 416 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2024

Primary endpoint
31 December 2026

31 December 2029

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	416
Start date	1 December 2024
Primary completion	31 December 2026
Estimated completion	31 December 2029
Sites	1 location across China

Drugs / interventions tested

Tislelizumab + SOX Chemotherapy — full drug profile →
SOX Chemotherapy — full drug profile →

Conditions studied

Gastric Cancer Stage III — all drugs for Gastric Cancer Stage III →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 80, any sex, with Gastric Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with stage III gastric or gastroesophageal junction adenocarcinoma who are ctDNA-MRD positive after surgery. The study will enroll 416 patients across multiple centers and will compare outcomes between two groups: patients receiving tislelizumab plus SOX chemotherapy and those receiving standard SOX chemotherapy alone. The primary questions to be addressed are whether the combination therapy improves 1-year DFS rates and whether it demonstrates an acceptable safety profile. Participants will provide tissue and blood samples for ctDNA-MRD testing, undergo postoperative adjuvant therapy (chemotherapy ± immunotherapy), and complete regular follow-up visits to monitor treatment response and safety. The trial will assess key outcomes, including DFS, overall survival (OS), and ctDNA clearance rates, to determine the clinical benefit and safety of tislelizumab in this population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastric Cancer Stage III

Currently open trials in the same condition.

NCT07257575 — A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma · Phase 2 · active not recruiting
NCT06755554 — Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer · Phase 3 · recruiting
NCT06042998 — A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer · NA · recruiting
NCT04515615 — Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) · Phase 2 · active not recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06939439 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 1 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06939439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing